MedPath

Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients

Not Applicable
Conditions
Renal Failure
Interventions
Drug: 0.9%NaCl solution
Registration Number
NCT02874378
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Brief Summary

Postoperative renal function recovery is very important to value the operation quality after kidney transplantation. Dexmedetomidine is a selective alpha-2 agonist,enhances urine flow rate and perioperative renal function. Some animal experiments have revealed its beneficial effects against ischemia-reperfusion injury (IRI), our goal is therefore to investigate the effectiveness of a recipient treatment with Dexmedetomidine during operation at reducing Cystatin C level and enhancing renal function after kidney transplantation.

Detailed Description

Participants will be randomly assigned, in a 1:1 ratio, to receive Dexmedetomidine or control (0.9 %Sodium Chloride Solution,0.9%NaCl). The randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center.Dexmedetomidine and 0.9 %NaCl solution will be treated from 10 minutes before anesthesia induction, ending in the last 10 minutes before the operation to complete. Cystatin C level and urine volume (but are not limited to these data) at 1,7,14 days after the transplantation will be recorded. The participation of each patient is scheduled for 14 days.Investigators will research both living and cadaveric kidney transplants.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients underwent renal transplant in the First Affiliated Hospital of Xi'an Jiaotong University.

Exclusion Criteria

severe comorbidity history: severe cardiac dysfunction, central nervous system disease, endocrine, and history of mental disorders; alcoholic and long-term use of sedatives and opioids history; drug allergy history.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
control group0.9%NaCl solution0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
study groupDexmedetomidineDexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
Primary Outcome Measures
NameTimeMethod
Cystatin C level2 weeks
Secondary Outcome Measures
NameTimeMethod
average daily urinary volume2 weeks
length of hospital stay (LOS)an expected average of 2 weeks
Wake up time, extubation time,SAS score,PONVup to 6 hours
total dosage of remifentanilup to 4 hours
Cr/GFR improvement2 weeks

Trial Locations

Locations (1)

the 1st affiliated hospital of Xi'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

© Copyright 2025. All Rights Reserved by MedPath